Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Innovative fluorescence-based diagnostic system identifies early-stage bladder cancer with 90% accuracy, utilizing untreated ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...

The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...